SCHEMBL4377399

SCHEMBL4377399

COc1cc2c(Oc3ccc4[nH]c(C)cc4c3)ncnc2cc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.56
FLT4 P35916 3/20 0.56
PDGFRB P09619 2/20 0.56
FLT3 P36888 2/20 0.56
KDM1A O60341 2/20 0.53
IRAK1 P51617 1/20 0.53
IRAK4 Q9NWZ3 1/20 0.53
KDR P35968 11/20 0.52
RET P07949 3/20 0.52
KIF5B P33176 1/20 0.52
KIT P10721 2/20 0.50
PDGFRA P16234 2/20 0.50
EGFR P00533 4/20 0.49
LCK P06239 2/20 0.49
MET P08581 2/20 0.48
TEK Q02763 2/20 0.48
AURKB Q96GD4 2/20 0.48
AURKA O14965 1/20 0.48
FLT1 P17948 2/20 0.47
PLK4 O00444 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373058 0.86 KDM4E (0.47) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL664052 0.86 KDM1A (0.54) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL4371598 0.86 KDR (0.54) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL4374374 0.86 CSF1R (0.57) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL4373558 0.85 FLT4 (0.56) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL4388707 0.84 KDM1A (0.63) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL4374350 0.84 KDM1A (0.52) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL6032099 0.84 KDM1A (0.52) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL4373113 0.83 KDM1A (0.54) CSF1RFLT4PDGFRBFLT3KDM1A
SCHEMBL6030922 0.83 KDR (0.52) CSF1RFLT4PDGFRBFLT3KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR CSF1R 84/4885FLT4 4/4885PDGFRB 125/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 CSF1R 243/4885FLT4 1/4885PDGFRB 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.